Compare Tango Therapeutics Inc. (TNGX) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.01 (market cap $330.26M). The key difference: Tango Therapeutics Inc. is far larger — about 11.4× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 56 Days on average.
| TNGX | XDTE | |
|---|---|---|
Market Cap | $3.75B | $330.26M |
Volume | 9,619,106 | 54,618 |
Sector | Health | Income / Options Overlay |
52-Week High | $32.90 | $44.76 |
52-Week Low | $7.50 | $36.00 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.70 with no recent price movement. The technical picture appears bearish with moving averages signaling caution, while oscillators remain neutral. Recent news highlights concerns about the sustainability of XDTE's high yield strategy, with multiple articles questioning whether dividend payments represent true income or return of capital. The fund's weekly dividend payments range from $0.09 to $0.20, but analysts express skepticism about the underlying math.
The outlook for XDTE remains cautious as structural concerns about its covered call strategy persist. While the fund offers attractive weekly income, questions about yield sustainability and fee efficiency present significant risks. Investors should weigh the trade-offs between immediate income generation and potential long-term capital appreciation limitations in flat or rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
